Carisma Therapeutics nabs $59m Series B

Carisma Therapeutics Inc., a biopharmaceutical company, has raised $59 million in Series B funding.

1 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles